Exploiting macrophages as targeted carrier to guide nanoparticles into glioma

Oncotarget

Volumn 7, Issue 24, 2016, Pages 37081-37091

  Pang, Liang ^a   Qin, Jing ^a   Han, Limei ^a   Zhao, Wenjie ^b   Liang, Jianming ^a   Xie, Zhongyi ^a   Yang, Pei ^a   Wang, Jianxin ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Institute of Pharmaceutical Industry   (China)

Author keywords

Glioma; Hypoxic; Inflammation; Macrophages; Nanoparticles

Indexed keywords

DOXORUBICIN; DRUG CARRIER; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; NANOPARTICLE; POLYGLACTIN; ANTINEOPLASTIC ANTIBIOTIC; FLUORESCENT DYE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; FEMALE; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; SLOW DRUG RELEASE; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BRAIN; BRAIN TUMOR; CELL SURVIVAL; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; RAW 264.7 CELL LINE; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; FEMALE; FLUORESCENT DYES; GLIOMA; HUMANS; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; NANOPARTICLES; RAW 264.7 CELLS; SPHEROIDS, CELLULAR; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978080525     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9464     Document Type: Article

References (44)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet. 2003; 361: 323-331.
2. Madsen SJ, Baek SK, Makkouk AR, Krasieva T, Hirschberg H. Macrophages as Cell-Based Delivery Systems for Nanoshells in Photothermal Therapy. Ann Biomed Eng. 2012; 40:507-515.
3. Newton HB. Advances in strategies to improve drug delivery to brain tumors. Expert Rev Neurother. 2006; 6:1495-1509.
4. Zhan C, Lu W. The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery. Curr Pharm Biotechnol. 2012; 13:2380-2387.
5. Hawkins BT, Egleton RD. Pathophysiology of the bloodbrain barrier: animal models and methods. Curr Top Dev Biol. 2008; 80:277-309.
6. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol. 2002; 38:323-337.
7. Liu Y, Lu W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin Drug Deliv. 2012; 9:671-686.
8. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer. 2004; 4:806-813.
9. Gao X, Li C. Nanoprobes visualizing gliomas by crossing the blood brain tumor barrier. Small. 2014; 10:426-440.
10. Garg T, Bhandari S, Rath G, Goyal AK. Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. J Drug Target. 2015:1-23.
11. Lee S. Monocytes: a novel drug delivery system targeting atherosclerosis. Journal of Drug Targeting. 2014; 22:138-145.
12. Batrakova EV, Gendelman HE, Kabanov AV. Cell-mediated drug delivery. Expert Opin Drug Del. 2011; 8:415-433.
13. Tao Y, Ning M, Dou H. A novel therapeutic system for malignant glioma: nanoformulation, pharmacokinetic, and anticancer properties of cell-nano-drug delivery. Nanomedicine: Nanotechnology, Biology and Medicine. 2013; 9:222-232.
14. Baek SK, Makkouk AR, Krasieva T, Sun CH, Madsen SJ, Hirschberg H. Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J Neuro-Oncol. 2011; 104:439-448.
15. Brynskikh AM, Zhao Y, Mosley RL, Li S, Boska MD, Klyachko NL, Kabanov AV, Gendelman HE, Batrakova EV. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond). 2010; 5:379-396.
16. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. 2010; 140:883-899.
17. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867.
18. Fleige G, Nolte C, Synowitz M, Seeberger F, Kettenmann H, Zimmer C. Magnetic labeling of activated microglia in experimental gliomas. Neoplasia. 2001; 3:489-499.
19. Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer. 2005; 117:701-708.
20. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011; 11:393-410.
21. Choi MR, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, Akin D, Badve S, Sturgis J, Robinson JP, Bashir R, Halas NJ, Clare SE. A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Letters. 2007; 7:3759-3765.
22. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66:605-612.
23. Huang WC, Chiang WH, Cheng YH, Lin WC, Yu CF, Yen CY, Yeh CK, Chern CS, Chiang CS, Chiu HC. Tumortropic monocyte-mediated delivery of echogenic polymer bubbles and therapeutic vesicles for chemotherapy of tumor hypoxia. Biomaterials. 2015; 71:71-83.
24. Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012; 64:640-665.
25. Huang Y, Jiang Y, Wang H, Wang J, Shin MC, Byun Y, He H, Liang Y, Yang VC. Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev. 2013; 65:1299-1315.
26. He H, Ye J, Wang Y, Liu Q, Chung HS, Kwon YM, Shin MC, Lee K, Yang VC. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. Journal of Controlled Release. 2014; 176:123-132.
27. Stephan MT, Stephan SB, Bak P, Chen JZ, Irvine DJ. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials. 2012; 33:5776-5787.
28. Wong D, Prameya R, Dorovini-Zis K. Adhesion and migration of polymorphonuclear leukocytes across human brain microvessel endothelial cells are differentially regulated by endothelial cell adhesion molecules and modulate monolayer permeability. J Neuroimmunol. 2007; 184:136-148.
29. Penberthy TW, Jiang Y, Graves DT. Leukocyte adhesion molecules. Crit Rev Oral Biol Med. 1997; 8:380-388.
30. Choi J, Kim HY, Ju EJ, Jung J, Park J, Chung HK, Lee JS, Park HJ, Song SY, Jeong SY, Choi EK. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials. 2012; 33:4195-4203.
31. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5:487-95.
32. Chang Y-N, Guo H, Li J, Song Y, Zhang M, Jin J, Xing G, Zhao Y. Adjusting the Balance between Effective Loading and Vector Migration of Macrophage Vehicles to Deliver Nanoparticles. PLoS ONE. 2013; 8: e76024.
33. Baek SK, Makkouk AR, Krasieva T, Sun CH, Madsen SJ, Hirschberg H. Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J Neurooncol. 2011; 104:439-448.
34. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: An underestimated tool is catching up again. J Biotechnol. 2010; 148:3-15.
35. Fu J, Wang D, Mei D, Zhang H, Wang Z, He B, Dai W, Wang X, Zhang Q. Macrophage mediated biomimetic delivery system for the treatment of lung metastasis of breast cancer. J Control Release. 2015; 204:11-19.
36. Klyachko NL, Haney MJ, Zhao Y, Manickam DS, Mahajan V, Suresh P, Hingtgen SD, Mosley RL, Gendelman HE, Kabanov AV, Batrakova EV. Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. Nanomedicine (Lond). 2014; 9:1403-1422.
37. Haney MJ, Zhao Y, Li S, Higginbotham SM, Booth SL, Han HY, Vetro JA, Mosley RL, Kabanov AV, Gendelman HE, Batrakova EV. Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. Nanomedicine (Lond). 2011; 6:1215-1230.
38. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012; 2012:948098.
39. Zhang L, Han L, Qin J, Lu W, Wang J. The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain. Pharm Res. 2013; 30:2560-2572.
40. Tewes F, Munnier E, Antoon B, Ngaboni Okassa L, Cohen-Jonathan S, Marchais H, Douziech-Eyrolles L, Souce M, Dubois P, Chourpa I. Comparative study of doxorubicinloaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm. 2007; 66:488-492.
41. Sheng J, Han L, Qin J, Ru G, Li R, Wu L, Cui D, Yang P, He Y, Wang J. N-Trimethyl Chitosan Chloride-Coated PLGA Nanoparticles Overcoming Multiple Barriers to Oral Insulin Absorption. ACS Appl Mater Interfaces. 2015; 7:15430-15441.
42. Glass CK, Natoli G. Molecular control of activation and priming in macrophages. Nat Immunol. 2015; 17:26-33.
43. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2015; 19:20-27.
44. Gao H, Yang Z, Zhang S, Cao S, Pang Z, Yang X, Jiang X. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth. J Control Release. 2013; 172:921-928.